Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.52 |
| ▸ | PPARG | P37231 | 7/20 | 0.52 |
| ▸ | PPARD | Q03181 | 7/20 | 0.52 |
| ▸ | PPARA | Q07869 | 7/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21616868 | 1.00 | TSHR (0.57) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4004597 | 1.00 | TSHR (0.57) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL9340855 | 1.00 | TSHR (0.57) | TSHRLMNANFKB1PMP22GPR84 | |
| Hydrochloric Acid SCHEMBL9954751 | 0.98 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL17653549 | 0.98 | LMNA (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL1848872 | 0.90 | LMNA (0.50) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL1119140 | 0.88 | PPARG (0.61) | TSHRLMNAPPARGPPARDPPARA | |
| SCHEMBL1119147 | 0.88 | PPARG (0.61) | TSHRLMNAPPARGPPARDPPARA | |
| Pimelic Acid SCHEMBL15353467 | 0.82 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL28965375 | 0.82 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018376-A1 | AQUEOUS ADDITIVE SOLUTION FOR INK COMPOSITION, AQUEOUS COLORANT SOLUTION FOR INK COMPOSITION, INK COMPOSITION, INK COMPOSITION FOR INK JET RECORDING, AND INK JET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-2560976-A1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011131709-A1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2011-10-27 | — | — | WO | disclosed |
| CN-100412073-C | Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | DIMENSIONAL PHARM INC (US) | 2008-08-20 | — | — | CN | disclosed |
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
| CN-1665800-A | Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | DIMENSIONAL PHARM INC (US) | 2005-09-07 | — | — | CN | disclosed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | TSHR 110/4885LMNA 4410/4885NFKB1 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.